NASDAQ:CRVS Corvus Pharmaceuticals (CRVS) Stock Price, News & Analysis $7.21 -0.14 (-1.90%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Corvus Pharmaceuticals Stock (NASDAQ:CRVS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Corvus Pharmaceuticals alerts:Sign Up Key Stats Today's Range$7.14▼$7.5450-Day Range$3.49▼$7.3552-Week Range$1.05▼$7.54Volume837,243 shsAverage Volume294,938 shsMarket Capitalization$450.99 millionP/E RatioN/ADividend YieldN/APrice Target$10.83Consensus RatingModerate Buy Company OverviewCorvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.Read More… I want to be very real with you (Ad)Listen, I don’t come at my readers this direct very often, but here goes nothing: There is one strategy that has helped change my life and I’d like to think it has changed the lives of some of my readers, too. We’ve had success stories but I won’t even show you here because I don’t want you to get unrealistic expectations since individual results do vary. But the point is, this thing is the real deal. There’s a reason I consider it my flagship, even with all the market advantages I’ve discovered in recent years.Watch this URGENT training here! Corvus Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks42nd Percentile Overall ScoreCRVS MarketRank™: Corvus Pharmaceuticals scored higher than 42% of companies evaluated by MarketBeat, and ranked 733rd out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingCorvus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCorvus Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Corvus Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Corvus Pharmaceuticals are expected to decrease in the coming year, from ($0.45) to ($0.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corvus Pharmaceuticals is -16.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Corvus Pharmaceuticals is -16.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorvus Pharmaceuticals has a P/B Ratio of 9.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Corvus Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.44% of the outstanding shares of Corvus Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverCorvus Pharmaceuticals has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Corvus Pharmaceuticals has recently increased by 31.10%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCorvus Pharmaceuticals does not currently pay a dividend.Dividend GrowthCorvus Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.44% of the outstanding shares of Corvus Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverCorvus Pharmaceuticals has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Corvus Pharmaceuticals has recently increased by 31.10%, indicating that investor sentiment is decreasing significantly. News and Social Media1.9 / 5News Sentiment0.49 News SentimentCorvus Pharmaceuticals has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Corvus Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for CRVS on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Corvus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Corvus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders31.30% of the stock of Corvus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions46.64% of the stock of Corvus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Corvus Pharmaceuticals' insider trading history. Receive CRVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CRVS Stock News HeadlinesStockNews.com Lowers Corvus Pharmaceuticals (NASDAQ:CRVS) to SellOctober 14 at 5:30 AM | americanbankingnews.comCorvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell LymphomaSeptember 10, 2024 | globenewswire.comThe real reason Elon is fully endorsing TrumpElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. October 17, 2024 | Porter & Company (Ad)Corvus Pharmaceuticals Inc.September 9, 2024 | barrons.comCorvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | globenewswire.comCorvus Pharmaceuticals Inc (CRVS)August 20, 2024 | investing.comCorvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial ResultsAugust 6, 2024 | globenewswire.comCorvus Pharma Gets FDA's Fast-Track for Lymphoma TreatmentAugust 1, 2024 | marketwatch.comSee More Headlines CRVS Stock Analysis - Frequently Asked Questions How have CRVS shares performed this year? Corvus Pharmaceuticals' stock was trading at $1.76 at the beginning of the year. Since then, CRVS stock has increased by 309.7% and is now trading at $7.21. View the best growth stocks for 2024 here. How were Corvus Pharmaceuticals' earnings last quarter? Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.05. When did Corvus Pharmaceuticals IPO? Corvus Pharmaceuticals (CRVS) raised $75 million in an initial public offering on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company served as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers. Who are Corvus Pharmaceuticals' major shareholders? Top institutional investors of Corvus Pharmaceuticals include Avity Investment Management Inc. (0.04%). Insiders that own company stock include Richard A Md Miller, William Benton Jones, Leiv Lea and Linda Grais. View institutional ownership trends. How do I buy shares of Corvus Pharmaceuticals? Shares of CRVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Corvus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Corvus Pharmaceuticals investors own include NVIDIA (NVDA), Viking Therapeutics (VKTX), Advanced Micro Devices (AMD), ADMA Biologics (ADMA), Rockwell Medical (RMTI), Axcelis Technologies (ACLS) and Protagonist Therapeutics (PTGX). Company Calendar Last Earnings8/06/2024Today10/17/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRVS CUSIPN/A CIK1626971 Webwww.corvuspharma.com Phone(650) 900-4520FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$10.83 High Stock Price Target$21.00 Low Stock Price Target$3.50 Potential Upside/Downside+50.3%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,030,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-53.99% Return on Assets-44.75% Debt Debt-to-Equity RatioN/A Current Ratio3.62 Quick Ratio3.62 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.79 per share Price / Book9.13Miscellaneous Outstanding Shares62,551,000Free Float42,973,000Market Cap$450.99 million OptionableOptionable Beta1.14 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report This page (NASDAQ:CRVS) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMassive trading opportunity begins by October 21 October 21 could spark a mania among “next-generation” AI stocks. That’s the newest prediction from a Wall Str...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.